TX-PURIFY-FUEL
5.2.2020 00:05:11 CET | Business Wire | Press release
Purify Fuel, Inc. (PFI), creator of the nanO2 Combustion Catalyst® that helps diesel consumers save money and reduce emissions, announced today that it has signed an exclusive distribution deal with Kanoo Blue. Purify Fuel’s nanO2 Combustion Catalyst optimizes performance and fuel efficiency in Marine Gasoil (MGO), making MGO a more cost-effective solution than Very Low Sulphur Fuel Oil (VLSFO).
Blending nanO2 Combustion Catalyst with MGO allows shipowners to avoid the compatibility issues associated with VLSFO blends and the mechanical challenges associated with running on multiple fuel types while increasing efficiency and saving money.
Further, with the recent implementation of IMO 2020’s sweeping legislation effective January 1, 2020, VLSFO prices have increased above MGO. While this trend may not hold, VLSFO pricing at/or near MGO reinforces the case for using Purify Fuel’s nanO2 Combustion Catalyst.
Through the agreement, Kanoo will act as the exclusive distribution partner in the region, helping customers in the marine, mining, oil services, transportation and power generation markets to achieve cleaner and more efficient diesel. Kanoo Blue focuses on identifying and bringing to its clients the best breakthrough technologies currently available in the world of science and technology across a wide spectrum of business segments.
“This partnership is not just good economically for the region, but it’s also great for environmental sustainability,” says Bader Abdulaziz Kanoo, Kanoo Blue Chairman. “Purify Fuel’s nanO2 Combustion Catalyst solution will help diesel engines work more efficiently while simultaneously helping to reduce harmful emissions. The timing for Purify Fuel could not be better as the region and the world search for cleaner fossil fuel options.”
“This deal builds on our first exclusive distribution partnership with Mencast Holdings, making Purify Fuel’s nanO2 Combustion Catalyst available in three of the world’s largest refueling ports — Singapore, Fujairah, and Shanghai — with annual sales of more than 20 billion gallons,” says John Carroll, CEO of Purify Fuel. “Additionally, through the efforts of our marine lead, John ‘Fozzie’ Miller, VADM (Ret), United States Navy, we are well on our way to meeting our goal of being distributed in 60% of the world’s largest ports.”
This exciting partnership will be on display at the Middle East Bunkering Convention , in Dubai. If you are a shipowner in the region and would like to learn more about how to leverage nanO2 to save money and reduce emissions, please contact us by visiting www.purifyfuel.com to schedule a meeting.
About Kanoo Blue:
Kanoo Blue was established in Bahrain for the purpose of bringing disruptive technologies to the Middle East and Africa, in the field of Energy, Nano Technology, Industrial IT, Artificial Intelligence, Bio-Technology, Water and other much needed high-end technologies to the region. Kanoo Blue is also the commercial partner for Houston Technologies, Middle-East for its portfolio of leading-edge disruptive technologies.
About Purify Fuel:
Purify Fuel creates patented nanotechnology-based rare earth oxides to help large diesel operators save money and reduce emissions. Purify Fuel’s nanO2 Combustion Catalysts® are custom blended to optimize diesel fuel and biodiesel blends for marine, fracking, military, mining, power generation, and rail markets. The combustion catalysts increase energy harvested from each gram of fuel while reducing particulate matter emissions and soot created by incomplete combustion. Purify Fuel works directly with large consumers of diesel and biodiesel fuel to help them save money, increase power, and reduce emissions.
For more information on Purify Fuel, please visit www.purifyfuel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204006069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
